p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats. 2004

Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
Department of Physiology, College of Medicine, Konkuk University, Choongju, Korea.

We investigated whether the diminished contractile responsiveness to endothelin-1 (ET-1) is associated with the altered activation of mitogen-activated protein kinase (MAPK) in aortic smooth muscles from deoxycorticosterone acetate (DOCA)-salt hypertensive rats. ET-1 dose-dependently increased contractions in aortic smooth muscle strips, and the contractions were significantly attenuated in tissues from DOCA-salt hypertensive rats compared with those from sham-operated rats. The phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 was elevated by ET-1, with the magnitude and time-course being similar between strips. Although ET-1 also increased the phosphorylation of p38 MAPK in both strips, the increment was markedly lower in the strips from DOCA-salt hypertensive rats compared with sham-operated controls. 5-hydroxytryptamine (5-HT) increased vascular contraction and phosphorylation of both MAPK isoforms; these were greater in DOCA-salt hypertensive rats than in sham-operated rats. ET-1 also increased the phosphorylation of caldesmon, an actin-binding protein, in sham-operated and DOCA-salt hypertensive rats. However, the increment was markedly lower in the strips from DOCA-salt hypertensive rats compared with sham-operated controls. The phosphorylation of MAPK isoforms and caldesmon elevated by ET-1 was inhibited by PD098059, an inhibitor of ERK1/2 kinase, and SB203580, an inhibitor of p38 MAPK, respectively. These results suggest that ET-1 and 5-HT induce contraction by activating the MAPK pathway in rat aortic smooth muscle and that the diminished responsiveness to ET-1 in the DOCA-salt hypertensive rat may be, in part, mediated by the decrease of caldesmon phosphorylation after the decreased activation of p38 MAPK.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002148 Calmodulin-Binding Proteins Proteins which bind calmodulin. They are found in many tissues and have a variety of functions including F-actin cross-linking properties, inhibition of cyclic nucleotide phosphodiesterase and calcium and magnesium ATPases. Caldesmon,Calspectin,CaM-BP(80),Caldesmon (77),Calmodulin Binding Proteins,Proteins, Calmodulin-Binding
D003900 Desoxycorticosterone A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE 21-Hydroxyprogesterone,Cortexone,Deoxycorticosterone,Desoxycortone,11-Decorticosterone,21-Hydroxy-4-pregnene-3,20-dione,11 Decorticosterone,21 Hydroxy 4 pregnene 3,20 dione,21 Hydroxyprogesterone

Related Publications

Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
July 2000, European journal of pharmacology,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
March 1990, Biochemical and biophysical research communications,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
August 2005, Peptides,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
September 1999, Molecular and cellular biochemistry,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
December 1996, British journal of pharmacology,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
February 1999, FEBS letters,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
December 2007, Molecular pharmacology,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
February 1999, Endocrinology,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
February 2005, American journal of physiology. Heart and circulatory physiology,
Bokyung Kim, and Junghwan Kim, and Young M Bae, and Sung I Cho, and Seong C Kwon, and Jin Y Jung, and Jung-C Park, and Hee Y Ahn
December 2000, Life sciences,
Copied contents to your clipboard!